Blanchet O - Search Results

1

Molecular approaches to the relationships between HLA and susceptibility to diseases.

Degos L, Khalil I, Blanchet O, Lepage V, Paul P, Hors J. Degos L, et al. Among authors: blanchet o. Adv Nephrol Necker Hosp. 1992;21:13-22. Adv Nephrol Necker Hosp. 1992. PMID: 1566643 Review. No abstract available.

2

Altered binding of regulatory factors to HLA class I enhancer sequence in human tumor cell lines lacking class I antigen expression.

Blanchet O, Bourge JF, Zinszner H, Israel A, Kourilsky P, Dausset J, Degos L, Paul P. Blanchet O, et al. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3488-92. doi: 10.1073/pnas.89.8.3488. Proc Natl Acad Sci U S A. 1992. PMID: 1565643 Free PMC article.

3

DNA binding of regulatory factors interacting with MHC-class-I gene enhancer correlates with MHC-class-I transcriptional level in class-I-defective cell lines.

Blanchet O, Bourge JF, Zinszner H, Tatari Z, Degos L, Paul P. Blanchet O, et al. Int J Cancer Suppl. 1991;6:138-45. doi: 10.1002/ijc.2910470725. Int J Cancer Suppl. 1991. PMID: 1906051

4

Multiple nuclear factors bind to novel positive and negative regulatory elements upstream of the human MHC class I gene HLA-A11.

Blanchet O, Gazin C, L'Haridon M, Tatari Z, Degos L, Sigaux F, Paul P. Blanchet O, et al. Int Immunol. 1994 Oct;6(10):1485-96. doi: 10.1093/intimm/6.10.1485. Int Immunol. 1994. PMID: 7826940

5

A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society.

Espérou H, Boiron JM, Cayuela JM, Blanchet O, Kuentz M, Jouet JP, Milpied N, Cahn JY, Faucher C, Bourhis JH, Michallet M, Tanguy ML, Vernant JP, Gabert J, Bordigoni P, Ifrah N, Baruchel A, Dombret H; French Bone Marrow Transplantation. Espérou H, et al. Among authors: blanchet o. Bone Marrow Transplant. 2003 May;31(10):909-18. doi: 10.1038/sj.bmt.1703951. Bone Marrow Transplant. 2003. PMID: 12748668

6

ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signalling.

Goossens S, Radaelli E, Blanchet O, Durinck K, Van der Meulen J, Peirs S, Taghon T, Tremblay CS, Costa M, Farhang Ghahremani M, De Medts J, Bartunkova S, Haigh K, Schwab C, Farla N, Pieters T, Matthijssens F, Van Roy N, Best JA, Deswarte K, Bogaert P, Carmichael C, Rickard A, Suryani S, Bracken LS, Alserihi R, Canté-Barrett K, Haenebalcke L, Clappier E, Rondou P, Slowicka K, Huylebroeck D, Goldrath AW, Janzen V, McCormack MP, Lock RB, Curtis DJ, Harrison C, Berx G, Speleman F, Meijerink JP, Soulier J, Van Vlierberghe P, Haigh JJ. Goossens S, et al. Among authors: blanchet o. Nat Commun. 2015 Jan 7;6:5794. doi: 10.1038/ncomms6794. Nat Commun. 2015. PMID: 25565005 Free PMC article.

7

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O, Blanchet O, Marit G, Gluckman E, Reiffers J, Gardembas M, Mahon FX. Rousselot P, et al. Among authors: blanchet o. Blood. 2007 Jan 1;109(1):58-60. doi: 10.1182/blood-2006-03-011239. Epub 2006 Sep 14. Blood. 2007. PMID: 16973963 Free article. Clinical Trial.

8

Deregulated expression of the TAL1 gene by t(1;5)(p32;31) in patient with T-cell acute lymphoblastic leukemia.

François S, Delabesse E, Baranger L, Dautel M, Foussard C, Boasson M, Blanchet O, Bernard O, Macintyre EA, Ifrah N. François S, et al. Among authors: blanchet o. Genes Chromosomes Cancer. 1998 Sep;23(1):36-43. doi: 10.1002/(sici)1098-2264(199809)23:1<36::aid-gcc6>3.0.co;2-7. Genes Chromosomes Cancer. 1998. PMID: 9713995

9

Expression of the cell cycle regulators p14(ARF) and p16(INK4a) in chronic myeloid leukemia.

Cividin M, Ayrault O, Sorel N, Séité P, Brizard F, Blanchet O, Mahon FX, Guilhot F, Larsen C, Chomel JC, Brizard A. Cividin M, et al. Among authors: blanchet o. Leuk Res. 2006 Oct;30(10):1273-8. doi: 10.1016/j.leukres.2006.02.002. Epub 2006 Mar 14. Leuk Res. 2006. PMID: 16533530

10

Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial.

Willekens C, Blanchet O, Renneville A, Cornillet-Lefebvre P, Pautas C, Guieze R, Ifrah N, Dombret H, Jourdan E, Preudhomme C, Boissel N; French AML Intergroup. Willekens C, et al. Among authors: blanchet o. Haematologica. 2016 Mar;101(3):328-35. doi: 10.3324/haematol.2015.131946. Epub 2015 Dec 3. Haematologica. 2016. PMID: 26635039 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

82 results

Search Page

Filters